CDNA insider plans sale of 46,963 shares

A Form 144 notice for CDNA reports a proposed sale of up to 46,963 shares of common stock through Morgan Stanley Smith Barney LLC on NASDAQ, with an aggregate market value of $2,178,945.34 as of 08/05/2026.

Rhea-AI Filing Summary

A Form 144 notice for CDNA reports a proposed sale of up to 46,963 shares of common stock through Morgan Stanley Smith Barney LLC on NASDAQ, with an aggregate market value of $2,178,945.34 as of 08/05/2026. The planned sales relate to restricted stock grants of 3,268 and 10,570 shares and a stock option exercise covering 33,125 shares. The notice also lists that Peter Maag sold 75,653 shares of common stock for $3,576,851.19 on 08/04/2026 within the prior three months.

Key Figures

Planned shares to be sold: 46,963 shares Aggregate market value of planned sale: $2,178,945.34 Shares sold in past 3 months: 75,653 shares +4 more

7 metrics

Planned shares to be sold 46,963 shares Common stock covered by Form 144 through Morgan Stanley Smith Barney LLC

Aggregate market value of planned sale $2,178,945.34 Value of 46,963 shares as of 08/05/2026

Shares sold in past 3 months 75,653 shares Common stock sale on 08/04/2026 by Peter Maag

Proceeds from recent sale $3,576,851.19 Total consideration for 75,653 shares sold on 08/04/2026

Restricted stock grant 1 3,268 shares Common stock from restricted stock dated 02/03/2025

Restricted stock grant 2 10,570 shares Common stock from restricted stock dated 06/14/2025

Stock option exercise shares 33,125 shares Common stock underlying stock option exercise dated 08/05/2026

Key Terms

Form 144, Restricted Stock, Stock Option Exercise, aggregate market value, +1 more

5 terms

Form 144 regulatory

"A Form 144 notice for CDNA reports a proposed sale"

Form 144 is a document that investors must file with the government when they plan to sell a large number of shares of a company's stock. It helps ensure transparency so everyone knows how many shares are being sold and when, which can impact the stock's price.

Restricted Stock financial

"Common | 02/03/2025 | Restricted Stock | Issuer"

Shares granted to an individual that carry limits on transfer or sale until certain conditions are met, such as staying with the company for a set time or hitting performance targets. Think of them as a locked gift that gradually opens; for investors they matter because they affect how many shares may enter the market later, signal management incentives and potential dilution, and reveal confidence in future company performance.

Stock Option Exercise financial

"Common | 08/05/2026 | Stock Option Exercise | Issuer"

A stock option exercise is the act of using a previously granted right to buy shares of a company's stock at a specific, predetermined price by paying that price and receiving the shares. It matters to investors because exercising changes who owns the shares (which can dilute existing ownership), can trigger taxable events and shift potential gains or losses, and affects voting power and the company’s outstanding share count—like turning a voucher into an actual product that becomes part of circulating supply.

aggregate market value financial

"with an aggregate market value of $2,178,945.34 as of 08/05/2026"

Aggregate market value is the combined price you would pay to buy all outstanding shares of a company or all companies in a group at current market prices — essentially the sum of each stock’s market capitalization. It matters to investors because it shows the overall size and weight of an investment or sector (like the total cost to buy every piece of a puzzle), helps compare scale across companies or markets, and influences index composition and risk exposure.

securities to be sold regulatory

"144: Securities To Be Sold Common | 02/03/2025"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What volume of CDNA common stock is proposed for sale in this Form 144?

The notice covers a proposed sale of up to 46,963 shares of CDNA common stock. These shares have an aggregate market value of $2,178,945.34 as of 08/05/2026 and are expected to trade on NASDAQ through Morgan Stanley Smith Barney LLC.

What types of CDNA awards are the source of the shares to be sold?

The planned CDNA share sales come from restricted stock and a stock option exercise. Specifically, 3,268 and 10,570 shares are tied to restricted stock grants, and 33,125 shares are associated with a stock option exercise dated 08/05/2026.

What recent CDNA stock sales are disclosed for the past three months?

The disclosure shows that 75,653 shares of CDNA common stock were sold on 08/04/2026. These shares were sold for total proceeds of $3,576,851.19, and the transaction is attributed to Peter Maag at a listed Brisbane, California address.

What is the reported market value of the CDNA shares subject to the planned sale?

The 46,963 CDNA shares covered by the notice have a reported aggregate market value of $2,178,945.34. This value is tied to the planned NASDAQ sale date of 08/05/2026 and reflects the market price used for Form 144 reporting purposes.

How many CDNA shares are linked to the stock option exercise in the notice?

The Form 144 identifies 33,125 shares of CDNA common stock related to a stock option exercise. This exercise is dated 08/05/2026 and is designated as a cash transaction, indicating the options are to be exercised for cash consideration.

How many CDNA shares are from restricted stock in the planned sale?

The planned sale includes CDNA shares from two restricted stock grants totaling 13,838 shares. One grant dated 02/03/2025 covers 3,268 shares, and another dated 06/14/2025 covers 10,570 shares, both listed as common stock of the issuer.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/05/2026 - 05:24 PM Accepted by SEC EDGAR 08/05/2026 - 05:23 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001613855
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	CAREDX, INC.
SEC File Number	001-36536
Address of Issuer	8000 Marina Boulevard, Brisbane CALIFORNIA 94005
Phone	415-287-2300
Name of Person for Whose Account the Securities are To Be Sold	PETER MAAG
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Director

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	46963	2178945.34	51734223	08/05/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	02/03/2025	Restricted Stock	Issuer			3268	02/03/2025	Not Applicable
Common	06/14/2025	Restricted Stock	Issuer			10570	06/14/2025	Not Applicable
Common	08/05/2026	Stock Option Exercise	Issuer			33125	08/05/2026	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
PETER MAAG 8000 Marina Boulevard, Brisbane CA 94005	Common	08/04/2026	75653	3576851.19

144: Remarks and Signature

Remarks
Date of Notice	08/05/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Peter Maag
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)